Bacteria in the Staphylococcus and Pseudomonas genuses have developed into antibiotic-resistant strains that have caused increases in infections and deaths in the United States. Gallium nitrate was just approved by the FDA to treat these infections; however, our group discovered that Pseudomonas develops drug resistance to this treatment in as little as four days of consecutive treatments, possibly due to the cationic nature of the gallium species and Pseudomonas control over its ion channels. In this research, we studied the effects of other gallium complexes, namely gallium acetylacetonoate, on Staphylococcus and Pseudomonas bacteria. We tried different methods of solvating gallium complexes, and then tested the effectiveness of these complexes in minimum inhibitory concentration (MIC) resistance studies.